CNX-2006
Catalog No. A13755
CNX-2006是一种有效的突变体选择性EGFR抑制剂，在具有激活性EGFR突变的细胞以及具有T790M突变的细胞中具有出色的体外活性。CNX-2006是CO-1686的原型，目前正在I期临床试验中，用于治疗EGFR突变型肺癌。
| Catalog Num | A13755 |
|---|---|
| M. Wt | 545.53 |
| Formula | C26H27F4N7O2 |
| Purity | >98% |
| Storage | at -20°C 3 years Powder |
| CAS No. | 1375465-09-0 |
| Synonyms | CNX2006, CNX 2006 |
| SMILES | COC1=C(C=CC(=C1)NC2CN(C2)CCF)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F |
CNX-2006是一种有效的突变体选择性EGFR抑制剂，在具有激活性EGFR突变的细胞以及具有T790M突变的细胞中具有出色的体外活性。CNX-2006是CO-1686的原型，目前正在I期临床试验中，用于治疗EGFR突变型肺癌。
| In vitro | DMSO | 90 mg/mL (164.97 mM) | |
| Water | Insoluble | ||
| Ethanol | 26 mg/mL (47.65 mM) | ||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 18.33 mL | 91.65 mL | 183.31 mL |
| 0.5 mM | 3.67 mL | 18.33 mL | 36.66 mL |
| 1 mM | 1.83 mL | 9.17 mL | 18.33 mL |
| 5 mM | 0.37 mL | 1.83 mL | 3.67 mL |
*The above data is based on the productmolecular weight 545.53. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
Contact information
United StatesAdooq Bioscience
Toll Free: (866) 930-6790
Fax: +1-323-606-8156
Email: sales@adooq.com
ADOOQ 产品质量保证
We promise all products to perform as described.